Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


Recent & Breaking News (TSX:EDT)

FDA Grants 510(k) Clearance for Spectral's Proprietary Stand-Alone Pump

Marketwired December 18, 2017

Spectral to Launch Toraymyxin(TM)/EAA(TM) in Canada in Q1 2018

Marketwired December 13, 2017

Spectral Announces Third Quarter Results

Marketwired November 14, 2017

Spectral Provides Update on FDA Meeting Regarding Its PMA Submission for Toraymyxin(TM)

MarketWire Canada October 31, 2017

Spectral Announces Retirement of Chief Financial Officer

MarketWire Canada October 18, 2017

Spectral Presents Key EUPHRATES Trial Data at the Canadian Critical Care Forum

MarketWire Canada October 4, 2017

Spectral Provides Regulatory Update on Its PMA Submission for Toraymyxin(TM)

MarketWire Canada September 21, 2017

Spectral Announces Second Quarter Results

MarketWire Canada August 11, 2017

FDA Accepts Spectral's PMA for Toraymyxin(TM) for Review

MarketWire Canada July 24, 2017

Spectral's Trial Data to Be Presented at 35th Vicenza Course on AKI and CRRT

MarketWire Canada June 12, 2017

Spectral Announces Voting Results of Annual Meeting

MarketWire Canada June 1, 2017

Spectral Files Final PMA Module for Toraymyxin(TM) With FDA

MarketWire Canada May 30, 2017

Spectral Announces First Quarter Results

MarketWire Canada May 12, 2017

Spectral Expands Distribution of EAA(TM) In the Middle and Far East and in Europe

Marketwired April 26, 2017

Spectral Announces Fourth Quarter and Fiscal 2016 Results

Marketwired March 30, 2017

U.S. FDA Approves Spectral's Third PMA Module for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock

MarketWire Canada March 7, 2017

Spectral to File Final PMA Module With the FDA for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock

MarketWire Canada February 23, 2017

Spectral Voluntarily Delists From OTCQX

MarketWire Canada December 14, 2016

Spectral Announces Appointment of Dr. Masayuki Kaneko to Its Board of Directors

MarketWire Canada December 5, 2016

Spectral Announces Next Steps in Path Forward and Issues Third Quarter Results

MarketWire Canada November 11, 2016